The FDA is proposing an “optional, risk-based” expedited Investigational New Drug pathway designed to move certain experimental drugs into human testing faster, aligning with a framework the agency says has shifted early development activity toward China. The idea would enable a quicker route to U.S. Phase 1 trials when existing preclinical data can be confirmed without animal studies, reducing time and development cost. The policy proposal would require Congressional action and would be implemented via a new regulatory mechanism rather than an immediate, standalone change. The agency’s stated goal is to create a more accelerated path for clinical initiation when the evidentiary package is considered sufficient. For biotechs, the practical impact is potential re-framing of preclinical data strategy and timing—particularly for programs that already have robust nonclinical evidence but face delays tied to traditional requirements. Separately, Takeda’s decision to end a co-development deal with Denali (DNL593) is described as driven by strategy rather than safety or efficacy, underscoring how companies are still adjusting portfolios amid regulatory uncertainty and internal restructuring.